They Call It a Lottery Ticket. The Data Says Otherwise | The Hidden Alpha of Biotech
TL;DR
Biotech investing is not gambling but a systematic 'bag of options' exercise where specialist investors can generate persistent alpha by probability-weighting drug development pipelines, though the sector experiences violent capital cycles driven by interest rates and competition from technology narratives like AI.
💊 The 'Bag of Options' Framework 3 insights
Development-stage firms as option portfolios
Early-stage biotech companies represent collections of call options on future drug approvals rather than traditional cash-flow businesses, with valuation requiring a sum-of-the-parts analysis of each independent program.
Probability-weighted valuation math
Investors calculate net present value by multiplying potential market size by phase-specific success probabilities—where preclinical drugs carry only 5-10% approval odds—and discounting cash flows occurring 8-10 years in the future.
Extreme duration risk
These companies exhibit severe sensitivity to interest rate changes because nearly 100% of their value derives from distant future cash flows, making valuations vulnerable to discount rate volatility.
🎯 Exploiting Information Asymmetry 3 insights
Domain expertise creates market inefficiency
Unlike efficient markets theory, biotech offers persistent alpha because proper valuation requires processing highly specialized scientific information that generalist investors cannot easily access or analyze.
Base rate analysis by modality
Successful investors anchor probability estimates using historical transition rates between clinical phases, adjusting for specific drug types such as antibodies versus small molecules to create precise reference classes.
Dual-variable valuation challenge
Accurate pricing depends on correctly estimating both the probability of technical success and the ultimate commercial opportunity (TAM), including uncertainties around pricing power and market share capture.
📈 Capital Cycles and Market Timing 3 insights
The COVID boom-bust cycle
The sector experienced extreme enthusiasm during the pandemic driven by mRNA vaccine success, followed by a 2022-2024 contraction as rising interest rates and capital rotation into AI/big tech drained risk capital from biotech.
2025 resurgence
Capital began flowing back into biotech by mid-2025, driving passive index returns of 80-100% as risk appetite returned and the sector emerged from its cyclical trough.
AI as capital competitor
Despite transformative narratives from figures like Jensen Huang, AI primarily competes with biotech for risk capital rather than driving sector inflows, with large pharma using AI stories to attract investment without establishing durable competitive advantages.
Bottom Line
Treat biotech companies as probability-weighted option portfolios and apply specialized domain knowledge to identify mispricings during periods of cyclical capital dislocation when generalist investors flee the sector.
More from Excess Returns
View all
46 Firms. 100 Years. Half of All Market Wealth | The Hidden Math of 100 Baggers
Just 46 companies generated half of all stock market wealth over the past century, demonstrating that extreme outliers drive returns and investors should study these rare '100-baggers' for identifiable traits rather than relying solely on statistical base rates that assume mean reversion.
The War No One Can Price | The Weekly Wrap – 3/22/2026
Markets often exhibit 'willful ignorance' toward obvious geopolitical threats like war until they materialize, while current options data shows a historic disconnect between implied volatility (VIX ~22) and realized volatility, indicating heavy hedging that could trigger sharp moves when protective positions expire.
A 3% Drop from VIX 40 | What the Options Market Tells Us About What Comes Next
Options markets are exhibiting unusual dynamics with VIX elevated at 25 despite low realized volatility, indicating investors are heavily hedged against 'known unknowns' like geopolitical risks. This creates a dangerous setup where the unwind of OPEX hedges could trigger sudden volatility expansion and sharp market drawdowns.
Down 50%. Up 200% | Jared Dillian on the Regime Change Investors Aren't Ready For
Jared Dillian argues markets structurally fail to price low-frequency, high-impact events due to 'willful ignorance,' while the post-2020 inflationary regime has broken the 60/40 portfolio by flipping stock-bond correlations positive, requiring investors to abandon outdated playbooks and embrace radical adaptability.